Thomas W. Sun, Ph.D.
Vice President, Nonclinical Development
Tom Sun is the Vice President of Nonclinical Development at Nuredis. He is responsible for medicinal chemistry, CMC and other aspects of nonclinical development. Prior to joining Nuredis, Tom was Vice President of Pharmaceutics and Manufacturing at Rigel Pharmaceuticals, Inc. He was a co-inventor of fostamatinib and played a key role in establishing the CMC strategy, the product development and manufacturing, and the NDA of fostamatinib. Tom and his team developed oral solid and liquid products, nasal spray, ophthalmic solution and topical ointment and contributed to the advancement of nine new chemical entities to clinical studies. Tom began his industry career at Roche Nutley and then moved to Roche Palo Alto. He worked at Roche for 6 years in the areas of process development, pharmaceutical chemistry and product development. Tom received his B.S. degree in Chemical Engineering and his M.S. degree in Chemistry from Dalian University of Technology, and his Ph.D. in Organic Chemistry from the University of California, Santa Cruz.